Company intelligence / Profile preview

Silk Technologies, Ltd.

Plymouth / Minneapolis area*, Minnesota, United Statessilk-tech.com ↗

Ownership: Private
Employees: ~8
Development stage: Preclinical

Overview

Preclinical data show that SDP‑4 has potent anti-inflammatory activity targeting causes of dry eye disease. It also improves wetting properties of ophthalmic formulations enhancing patient comfort without causing blurred vision due to viscosity increase. The drug candidate aims to provide superior symptom relief compared to existing therapies[3].

Therapeutic areas: Ophthalmology
Modalities: Silk-Derived Protein (SDP) based biological drugs and productsAnti-inflammatory biologics for ophthalmic use
Industry: Biotech

Drug pipeline

1 asset

amlisimod

Partnerships

Investment partnership with Skyview Ventures supporting clinical development[3]

Beyond the preview

Go deeper on Silk Technologies, Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Silk Technologies, Ltd..

Explore the full profile